NCT00105521View on ClinicalTrials.gov

Sarizotan in Participants With Parkinson's Disease Suffering From Treatment Associated Dyskinesia

PHASE3CompletedINTERVENTIONAL

Enrollment

398

Participants

Timeline

Start Date

September 30, 2004

Primary Completion Date

March 31, 2006

Study Completion Date

March 31, 2006

Conditions

Parkinson's DiseaseDyskinesia

Interventions

DRUG

Sarizotan

Sarizotan will be administered twice daily.

DRUG

Placebo

Placebo matching to sarizotan will be administered twice daily.

Trial Locations (32)

10003

New York

12205

Albany

13210

Syracuse

18103

Allentown

19013

Upland

19107

Philadelphia

21044

Columbia

21207

Baltimore

22903

Charlottesville

33021

Hollywood

33334

Fort Lauderdale

33612

Tampa

33703

St. Petersburg

33952

Port Charlotte

34471

Ocala

40503

Lexington

55427

Golden Valley

60194

Hoffman Estates

60612

Chicago

68131

Omaha

75231

Dallas

85004

Phoenix

85013

Phoenix

85032

Phoenix

85259

Scottsdale

90033

Los Angeles

92708

Fountain Valley

372703

Fayetteville

60611-3078

Chicago

02118-2526

Boston

02215

Boston

43614-5811

Toledo

Sponsors

Lead Sponsor

All Listed Sponsors

lead

EMD Serono

INDUSTRY

NCT00105521 - Sarizotan in Participants With Parkinson's Disease Suffering From Treatment Associated Dyskinesia | Biotech Hunter | Biotech Hunter